Related Experiment Video
Updated: May 1, 2026
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
Published on: April 29, 2015
Dissecting lipid nanoparticle adjuvanticity and reactogenicity to optimize vaccine formulations.
Toshiro Hirai1, Yasuo Yoshioka2
1Laboratory of Nano-Design for Innovative Drug Development, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka, Japan; Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, The University of Osaka, Osaka, Japan; Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka, Osaka, Japan; Center for Advanced Modalities and DDS, The University of Osaka, Osaka, Japan.
Lipid nanoparticles (LNPs) enable mRNA vaccines but cause side effects. Different LNP formulations can be designed to tune immune responses, potentially leading to safer and more effective vaccines.
Area of Science:
- Vaccinology
- Immunology
- Nanotechnology
Background:
- mRNA vaccines offer high efficacy but can be reactogenic.
- Lipid nanoparticles (LNPs) are crucial for mRNA delivery and innate immune stimulation.
- The reactogenicity of mRNA vaccines is linked to LNP adjuvant properties.
Purpose of the Study:
- To review recent advances in understanding LNP-mediated innate immune sensing.
- To explore the relationship between LNP formulation, adjuvanticity, and reactogenicity.
- To outline principles for designing safer and more effective LNP-based vaccines.
Main Methods:
- Review of current literature on LNP-innate immune interactions.
- Analysis of how LNP formulation influences immune signatures.
- Discussion of strategies to uncouple adjuvanticity and reactogenicity.
Main Results:
- LNP adjuvanticity is formulation-dependent, eliciting distinct innate immune programs.
- Immune responses and reactogenicity can be modulated by tuning LNP properties and in vivo distribution.
- Adjuvanticity and reactogenicity may be partially dissociable outcomes.
Conclusions:
- Rational LNP design can optimize vaccine adjuvanticity and minimize reactogenicity.
- Understanding LNP-innate immune interactions is key to developing next-generation vaccines.
- Tailoring LNP formulations offers a pathway to safer and more effective vaccine options.
More Related Videos
06:02Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination
Published on: February 23, 2024
07:32Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023